1. A 66-year-old man was diagnosed with Parkinson's disease four months ago and started on carbidopa/levodopa 25/100 mg three times daily. His morning dose works well, providing good motor control for several hours. His midday and afternoon doses are unreliable — he notices that on days when he eats a full lunch with meat and cheese before taking his noon pill, he gets little benefit for the next two hours. On days when he takes his noon pill 45 minutes before lunch, motor control is adequate. His neurologist wants to explain the mechanism and give practical dietary guidance. Which of the following best explains the pharmacokinetic mechanism of his inconsistent afternoon response and identifies the correct management strategy?
A) His inconsistent response reflects accelerated hepatic levodopa metabolism after protein-rich meals; dietary amino acids upregulate hepatic COMT activity, increasing conversion of levodopa to 3-O-methyldopa before it reaches the systemic circulation; management is to add a COMT inhibitor such as entacapone to block this meal-induced peripheral degradation
B) His inconsistent response reflects delayed gastric emptying after a protein-rich meal, which retards levodopa absorption from the proximal small intestine and creates a gap between the expected and actual peak plasma level; management is to switch to a dispersible (rapidly dissolving) levodopa formulation that is absorbed in the stomach rather than the duodenum
C) His inconsistent response reflects competition between dietary large neutral amino acids — phenylalanine, leucine, isoleucine, valine, tyrosine, and others — and levodopa for the large neutral amino acid transporter 1 (LAT1) at the blood-brain barrier; elevated postprandial plasma amino acid concentrations reduce CNS levodopa delivery despite adequate plasma drug levels; management includes taking levodopa 30–60 minutes before protein-containing meals and considering protein redistribution — concentrating dietary protein at the evening meal to minimize daytime LAT1 competition during the most active hours
D) His inconsistent response reflects a pharmacodynamic interaction between dietary tyrosine and striatal dopamine receptors; absorbed tyrosine is converted to dopamine in peripheral tissues after a protein meal, and this peripheral dopamine competes with centrally produced dopamine at postsynaptic D2 receptors in the striatum, blunting the therapeutic signal; management is to avoid tyrosine-containing foods around the time of levodopa doses
E) His inconsistent response reflects meal-induced insulin release, which drives large neutral amino acids into skeletal muscle; the resulting fall in plasma amino acid concentrations paradoxically increases LAT1 competition by upregulating the transporter; management is to take levodopa with a carbohydrate-only snack that maximizes insulin release and clears competing amino acids from the plasma before the drug reaches the blood-brain barrier
ANSWER: C
Rationale:
Levodopa crosses the blood-brain barrier exclusively via the large neutral amino acid transporter 1 (LAT1), a sodium-independent facilitated transporter that also carries endogenous large neutral amino acids — including phenylalanine, leucine, isoleucine, valine, tyrosine, tryptophan, methionine, and histidine — across the blood-brain barrier. When this patient eats a protein-rich lunch before taking his levodopa, the absorbed dietary amino acids raise plasma large neutral amino acid concentrations substantially, increasing competition at LAT1 and reducing the fraction of circulating levodopa successfully transported into the CNS. Because the problem is at the level of BBB transport rather than systemic absorption, plasma levodopa concentrations may be within the expected range while CNS delivery is impaired — explaining why he gets adequate motor control on days when the pill is taken before eating (less LAT1 competition at the time of peak plasma levodopa) but poor control when taken after a protein meal (high competing amino acid concentrations coincide with peak plasma levodopa). Practical management centers on two strategies: first, timing levodopa doses 30–60 minutes before protein-containing meals so that peak plasma levodopa precedes the postprandial amino acid rise; second, protein redistribution diets that concentrate dietary protein at the evening meal, minimizing large neutral amino acid competition during daytime hours when motor function is most needed. LAT1 is also responsible for intestinal levodopa absorption, so some benefit from pre-meal dosing also reflects improved intestinal absorption.
Option A: Option A is incorrect: dietary amino acids do not meaningfully upregulate hepatic COMT activity on a meal-to-meal basis; COMT activity is relatively constitutive; while COMT inhibitors do improve levodopa bioavailability, this is not the mechanism of his meal-related inconsistency, which is a BBB transport phenomenon.
Option B: Option B is incorrect: while delayed gastric emptying does contribute to levodopa pharmacokinetic variability in PD, it would produce delayed and reduced peak plasma levels, not the pattern of adequate morning response with inconsistent afternoon response specifically tied to protein intake; the clear relationship with protein content points to LAT1 competition.
Option D: Option D is incorrect: dietary tyrosine absorbed from a protein meal does not produce peripheral dopamine in quantities sufficient to compete at striatal D2 receptors; the enzymatic conversion of tyrosine to dopamine in peripheral tissues is tightly regulated and does not result in pharmacologically relevant peripheral dopamine competing centrally; this mechanism does not exist.
Option E: Option E is incorrect: postprandial insulin does drive amino acids into skeletal muscle, but this occurs over 60–90 minutes after the meal and would reduce rather than increase plasma amino acid concentrations; the claim that this paradoxically upregulates LAT1 to increase competition is not pharmacologically established; the problem occurs when amino acid levels are high, not when they are being cleared.
2. A 44-year-old woman with schizophrenia has been maintained on haloperidol for three years. Over the past four months she has developed a resting tremor in her right hand, bradykinesia, and cogwheel rigidity. Her psychiatrist asks neurology to evaluate for Parkinson's disease. The neurologist considers ordering a DAT-SPECT (DaTscan) to clarify the diagnosis. Which of the following best explains the expected DaTscan result and the underlying mechanism that distinguishes this presentation from idiopathic Parkinson's disease?
A) In drug-induced parkinsonism caused by haloperidol, DAT-SPECT imaging would be expected to show normal or near-normal striatal dopamine transporter (DAT) binding because the presynaptic dopaminergic terminals are structurally intact; haloperidol blocks postsynaptic D2 receptors in the nigrostriatal pathway, producing a functional dopamine deficit at the receptor level without any loss of presynaptic terminals; in idiopathic PD, DAT binding is reduced in proportion to the loss of nigrostriatal terminals
B) In drug-induced parkinsonism caused by haloperidol, DAT-SPECT would show reduced striatal DAT binding indistinguishable from idiopathic PD because haloperidol directly competes with the DAT radiotracer for binding to the dopamine transporter, displacing the ligand and producing apparent DAT reduction; the scan normalizes within days of haloperidol discontinuation as tracer competition resolves
C) In drug-induced parkinsonism caused by haloperidol, DAT-SPECT would show bilaterally reduced DAT binding because haloperidol upregulates DAT expression on presynaptic terminals through a compensatory mechanism, and this upregulation paradoxically reduces available tracer binding sites; the increased DAT density is detected as reduced specific binding by the scanner algorithm
D) DAT-SPECT cannot distinguish drug-induced parkinsonism from idiopathic PD because both conditions produce identical patterns of reduced putaminal DAT binding; the only reliable distinguishing feature is the temporal relationship between drug initiation and symptom onset, and the DAT scan provides no additional diagnostic information beyond the clinical history
E) In drug-induced parkinsonism caused by haloperidol, DAT-SPECT would show asymmetrically reduced DAT binding contralateral to the more affected limb, identical to the early asymmetric pattern of idiopathic PD; haloperidol accelerates dopaminergic terminal loss by producing excitotoxic glutamate release from STN neurons that damages presynaptic dopaminergic terminals over months of treatment
ANSWER: A
Rationale:
Drug-induced parkinsonism (DIP) caused by haloperidol and other D2 receptor antagonists is a postsynaptic pharmacological phenomenon: haloperidol blocks D2 dopamine receptors on indirect pathway medium spiny neurons and at other striatal postsynaptic sites, preventing dopamine signal transduction and producing a functional dopamine deficit that manifests clinically as parkinsonism — tremor, bradykinesia, and rigidity similar to idiopathic PD. Critically, the presynaptic nigrostriatal dopaminergic terminals are structurally intact; haloperidol does not damage or destroy SNpc neurons or their axonal projections to the striatum. Because the dopamine transporter (DAT) is expressed exclusively on presynaptic dopaminergic terminals, DAT-SPECT imaging reflects the integrity of these terminals rather than postsynaptic receptor blockade. In DIP, DAT binding should therefore be normal or near-normal, in sharp contrast to idiopathic PD where DAT binding is reduced proportionally to the loss of nigrostriatal terminals. This distinction has direct clinical utility: a normal DaTscan in a patient with parkinsonism and recent antipsychotic exposure supports DIP as the diagnosis and argues against concurrent idiopathic PD, whereas a reduced DaTscan would indicate true nigrostriatal terminal loss and suggest idiopathic or drug-unmasked PD.
Option B: Option B is incorrect: haloperidol does not bind the DAT radiotracer's target site; ioflupane (DaTscan ligand) binds the dopamine transporter, and haloperidol is a D2 receptor antagonist with no significant DAT binding affinity; haloperidol does not compete with the DAT radiotracer, and a normal scan in DIP reflects intact terminals, not resolved tracer competition.
Option C: Option C is incorrect: haloperidol does not upregulate DAT expression as a compensatory mechanism that reduces apparent tracer binding; DAT expression may change modestly with chronic dopaminergic manipulation but this is not the mechanism by which DIP produces parkinsonism, and this explanation of apparent DAT reduction is pharmacologically unsupported.
Option D: Option D is incorrect: DAT-SPECT can distinguish DIP from idiopathic PD in the majority of cases; DIP typically shows normal or near-normal DAT binding while idiopathic PD shows reduced binding; the scan does provide clinically useful information beyond the history, particularly when the history is ambiguous or the patient may have drug-unmasked underlying PD.
Option E: Option E is incorrect: haloperidol does not cause excitotoxic loss of presynaptic dopaminergic terminals via STN-mediated glutamate release; this mechanism is not established; the parkinsonism of DIP is reversible upon drug discontinuation in most cases, consistent with a postsynaptic receptor blockade mechanism rather than structural terminal loss.
3. A 61-year-old man with early Parkinson's disease begins pramipexole at the standard starting dose of 0.125 mg three times daily. At his three-day follow-up call, he reports that his tremor and slowness seem slightly worse than before starting the drug. He asks whether he should stop the medication. Which of the following best explains the mechanism of his transient worsening and the correct management response?
A) His transient worsening reflects pramipexole-induced D1 receptor downregulation in the direct pathway; at starting doses, pramipexole has paradoxical high affinity for D1 receptors and reduces direct pathway MSN excitability; management is to switch to a D2-selective agonist that lacks D1 activity at low doses
B) His transient worsening reflects competitive displacement of endogenous dopamine from postsynaptic D2 receptors; pramipexole at low doses acts as a partial agonist with lower intrinsic activity than dopamine, reducing net D2 receptor signaling below baseline; management is to increase the dose rapidly to full agonist occupancy before the competitive effect dominates
C) His transient worsening reflects pramipexole-induced release of acetylcholine from striatal cholinergic interneurons; dopamine agonists at low doses paradoxically increase cholinergic interneuron firing through D4 receptor activation, elevating striatal acetylcholine and worsening tremor through the cholinergic-dopaminergic imbalance; management is to add a low-dose anticholinergic agent during titration
D) His transient worsening reflects a nocebo effect — the expectation of side effects based on the medication information leaflet; pramipexole has no pharmacological mechanism that would worsen PD symptoms at starting doses; management is reassurance and continuation of the current dose without change
E) His transient worsening at low starting doses reflects preferential engagement of high-sensitivity presynaptic D2 autoreceptors on dopaminergic terminals and cell bodies in the substantia nigra; autoreceptor activation reduces endogenous dopamine synthesis via tyrosine hydroxylase inhibition and decreases vesicular release per action potential, transiently lowering net striatal dopamine below the pre-treatment baseline; as the dose is titrated upward, postsynaptic D2 and D3 receptors requiring higher agonist concentrations are engaged, producing the intended therapeutic benefit; he should continue the medication and proceed with the planned titration schedule
ANSWER: E
Rationale:
Pramipexole, like all dopamine agonists, acts at both presynaptic and postsynaptic dopamine receptors, but the two populations differ critically in their sensitivity: presynaptic D2 autoreceptors on dopaminergic terminals and on dopaminergic cell bodies and dendrites in the substantia nigra pars compacta have a lower EC50 for agonists than postsynaptic D2 receptors on striatal medium spiny neurons. At the low starting dose of 0.125 mg three times daily, plasma and CNS concentrations of pramipexole are sufficient to occupy and activate the high-sensitivity presynaptic autoreceptors meaningfully, while postsynaptic receptor occupancy remains low. Activated somatodendritic autoreceptors hyperpolarize dopaminergic neurons via Gi-coupled potassium channel activation, reducing their firing rate; terminal autoreceptors reduce the probability of vesicular dopamine release per action potential through calcium channel inhibition; and both populations inhibit tyrosine hydroxylase, reducing dopamine synthesis. The net effect is a transient reduction in endogenous striatal dopamine release below the pre-treatment baseline, producing a slight worsening of motor symptoms in the first days of treatment. This is a predictable and well-recognized pharmacodynamic phenomenon that resolves as the dose is incrementally increased: at therapeutic doses (typically 0.5–1.5 mg three times daily for PD), postsynaptic D2 and D3 receptor occupancy becomes sufficient to produce motor benefit that far outweighs the autoreceptor-mediated reduction in endogenous release. The patient should be reassured that this transient worsening is expected, and the titration should proceed according to the standard schedule.
Option A: Option A is incorrect: pramipexole has minimal D1 receptor affinity; it is a D2/D3-preferring agonist; D1 receptor downregulation is not the mechanism of early worsening at low doses.
Option B: Option B is incorrect: pramipexole is a full agonist at D2 and D3 receptors, not a partial agonist; it does not competitively displace endogenous dopamine as a lower-intrinsic-activity competitor; the early worsening is a presynaptic autoreceptor phenomenon, not competitive postsynaptic displacement.
Option C: Option C is incorrect: dopamine agonists do not increase cholinergic interneuron firing through D4 receptor activation; D4 receptor expression in the striatum is relatively low, and D4 activation is not an established mechanism by which dopamine agonists worsen tremor in early PD; the cholinergic mechanism of tremor is modulated by the dopamine-acetylcholine balance, but not through agonist-induced cholinergic interneuron stimulation at low doses.
Option D: Option D is incorrect: the autoreceptor-mediated worsening of motor symptoms at low dopamine agonist doses is a well-documented pharmacological phenomenon with a clear receptor mechanism; attributing it entirely to a nocebo effect dismisses established pharmacodynamics and would lead to inappropriate management.
4. A 58-year-old man with Parkinson's disease has been on pramipexole 1.0 mg three times daily for eight months with good motor control. His wife calls the clinic concerned that he has lost $14,000 gambling at a casino over the past three months — behavior completely out of character. He has no prior history of gambling. His motor symptoms are well controlled. Which of the following best identifies the mechanism responsible for this behavioral change and the appropriate management?
A) His pathological gambling represents a serotonin syndrome variant triggered by pramipexole's partial 5-HT1A agonist activity in the nucleus accumbens; the serotonergic overstimulation disinhibits reward circuits and drives compulsive behavior; management is to add a 5-HT1A antagonist such as buspirone to block the aberrant serotonergic signal while continuing pramipexole for motor benefit
B) His pathological gambling is an impulse control disorder caused by excessive dopaminergic stimulation of the mesolimbic pathway — specifically D3 receptors concentrated in the nucleus accumbens and ventral striatum; pramipexole has preferential D3 receptor affinity relative to other dopamine agonists; overstimulation of D3-rich limbic reward circuits produces aberrant incentive salience and compulsive reward-seeking behavior; management requires dose reduction or discontinuation of the dopamine agonist, with transition to levodopa if motor symptoms require ongoing treatment
C) His pathological gambling reflects levodopa-induced dopamine dysregulation syndrome rather than pramipexole toxicity; as a D2/D3 agonist, pramipexole has no limbic activity and cannot cause impulse control disorders; management is to reduce the levodopa dose and switch to pramipexole monotherapy, which does not affect mesolimbic reward circuits
D) His pathological gambling is caused by pramipexole-induced hyperprolactinemia from tuberoinfundibular pathway stimulation; elevated prolactin suppresses frontal lobe inhibitory control via PRL receptors in the prefrontal cortex, producing disinhibited reward-seeking behavior; management is to add cabergoline to normalize prolactin while continuing pramipexole
E) His pathological gambling reflects a direct toxic effect of pramipexole on prefrontal cortex neurons that regulate impulse inhibition; pramipexole's D3 agonist activity in the dorsolateral prefrontal cortex reduces GABAergic interneuron firing and impairs the cortical brake on impulsive behavior; management is to add a low-dose GABA-B agonist such as baclofen to restore prefrontal inhibitory tone
ANSWER: B
Rationale:
Impulse control disorders (ICDs) — including pathological gambling, hypersexuality, compulsive eating, and compulsive shopping — are a well-recognized class of adverse effects associated with dopamine agonist therapy for Parkinson's disease, with an estimated prevalence of 13–17% in treated patients. The mechanism involves excessive stimulation of the mesolimbic dopamine pathway, which projects from the ventral tegmental area to the nucleus accumbens (ventral striatum) and other limbic structures and mediates reward processing, motivational salience, and reinforcement learning. Pramipexole and ropinirole have preferential affinity for D3 receptors relative to D2, and D3 receptors are concentrated in the nucleus accumbens and limbic structures. Overstimulation of D3-rich mesolimbic circuits by the agonist lowers the threshold for reward-seeking behavior and impairs the normal suppression of maladaptive impulses, producing compulsive behaviors that are entirely out of character for the patient. ICDs are more common with dopamine agonists than with levodopa, consistent with the agonists' direct limbic receptor stimulation independent of nigrostriatal dopamine levels. Management requires dose reduction or discontinuation of the dopamine agonist; ICDs typically resolve or substantially improve within weeks. If motor symptoms require continued dopaminergic therapy, transition to levodopa — which produces less direct limbic stimulation — is often the preferred strategy.
Option A: Option A is incorrect: pramipexole does not have clinically significant 5-HT1A agonist activity; serotonin syndrome involves excessive serotonergic neurotransmission, not the reward-circuit-mediated compulsive behavior pattern seen with dopamine agonist ICDs; buspirone is a 5-HT1A partial agonist used for anxiety and is not the treatment for ICD.
Option C: Option C is incorrect: pramipexole does act on mesolimbic D2/D3 receptors and is the agent most commonly implicated in ICDs; the claim that it has no limbic activity is pharmacologically false; while levodopa-associated dopamine dysregulation syndrome does exist, the scenario describes a classic dopamine agonist ICD presentation.
Option D: Option D is incorrect: dopamine agonists acting at the tuberoinfundibular pathway reduce (not increase) prolactin by stimulating D2 receptors on lactotrophs; dopamine agonists cause hypoprolactinemia, not hyperprolactinemia; and prolactin does not regulate frontal lobe impulse control through the mechanism described.
Option E: Option E is incorrect: while D3 receptors are present in prefrontal cortex, the established mechanism of dopamine agonist ICDs is mesolimbic overstimulation, not direct prefrontal GABAergic interneuron suppression; baclofen is not an established treatment for dopamine agonist ICDs.
5. A 77-year-old woman with a 9-year history of Parkinson's disease begins experiencing nightly formed visual hallucinations — she sees small animals and children in her bedroom that she knows are not real. She is distressed and her sleep is disrupted. Her motor symptoms are reasonably controlled on carbidopa/levodopa. Her internist, unfamiliar with PD-specific prescribing constraints, considers starting risperidone. Which of the following best explains why risperidone is inappropriate and identifies the correct pharmacological alternatives?
A) Risperidone is inappropriate because its potent anticholinergic properties will worsen the cognitive impairment underlying PD psychosis; the correct alternatives are agents with no anticholinergic activity such as haloperidol or fluphenazine, which are the safest antipsychotics in PD because their pure D2 blockade is well tolerated in patients already on levodopa
B) Risperidone is inappropriate because it inhibits CYP2D6, reducing the metabolism of levodopa and causing toxic levodopa accumulation; the correct alternative is an antipsychotic that does not inhibit CYP2D6, such as aripiprazole, which is metabolically neutral and safe in PD patients on levodopa
C) Risperidone is inappropriate because it blocks serotonin 5-HT2A receptors, which are required for dopamine release in the striatum; 5-HT2A blockade reduces available striatal dopamine and worsens the existing dopamine deficit; the correct alternative is a pure D2 antagonist without 5-HT2A activity, such as haloperidol
D) Risperidone is inappropriate because it blocks D2 dopamine receptors in the nigrostriatal pathway with sufficient affinity to worsen the parkinsonian motor deficit in a patient who depends on marginal nigrostriatal dopamine reserve; acceptable alternatives are quetiapine or clozapine, which have low D2 affinity and rapid receptor dissociation kinetics minimizing nigrostriatal motor worsening, and pimavanserin, a selective 5-HT2A/5-HT2C inverse agonist with no dopamine receptor affinity that is FDA-approved specifically for PD psychosis
E) Risperidone is inappropriate because PD patients metabolize it to an active metabolite — 9-hydroxyrisperidone (paliperidone) — at an accelerated rate due to levodopa-induced CYP3A4 induction; the elevated active metabolite levels produce prolonged QTc interval and risk of torsades de pointes; the correct alternative is clozapine, which is not metabolized by CYP3A4 and does not prolong the QTc interval in PD patients
ANSWER: D
Rationale:
Risperidone is a second-generation antipsychotic with high affinity for D2 receptors — it produces approximately 65–80% D2 receptor occupancy at typical therapeutic doses. In neurologically intact patients this D2 blockade produces extrapyramidal side effects as a dose-dependent risk, but in a patient with advanced Parkinson's disease — where 60–70% or more of SNpc dopaminergic neurons have been lost and residual motor function depends on whatever nigrostriatal dopaminergic signaling remains — nigrostriatal D2 blockade produces significant, often severe motor deterioration. The acceptable antipsychotic options in PD are those with substantially lower nigrostriatal D2 impact: quetiapine has weak D2 affinity and rapid receptor dissociation, producing antipsychotic effect through limbic D2/D3 engagement with relatively less nigrostriatal motor consequence; clozapine at the low doses used for PD psychosis has very low nigrostriatal D2 occupancy, though it requires regular blood count monitoring due to agranulocytosis risk; and pimavanserin is a selective inverse agonist at serotonin 5-HT2A and 5-HT2C receptors with no affinity for any dopamine receptor subtype, achieving antipsychotic effect without any dopaminergic interaction — it is the only FDA-approved agent with a specific indication for hallucinations and delusions associated with Parkinson's disease psychosis.
Option A: Option A is incorrect: haloperidol and fluphenazine are high-potency typical antipsychotics with very high D2 affinity and are among the worst choices in PD — they regularly produce severe motor deterioration; risperidone is not contraindicated because of anticholinergic properties (risperidone has low anticholinergic activity); haloperidol is not safe in PD.
Option B: Option B is incorrect: risperidone is a moderate CYP2D6 inhibitor but this does not cause levodopa accumulation — levodopa is not metabolized by CYP2D6; its metabolism involves AADC and COMT; and aripiprazole frequently worsens motor function in PD despite not being a CYP2D6-based concern.
Option C: Option C is incorrect: 5-HT2A blockade is associated with reduced extrapyramidal side effects, not increased ones, in neurologically intact patients; pimavanserin's antipsychotic mechanism is 5-HT2A inverse agonism, and it does not worsen motor function; risperidone's problem in PD is its D2 receptor affinity, not its 5-HT2A blockade.
Option E: Option E is incorrect: the CYP3A4-induction-by-levodopa mechanism does not exist; levodopa is not a CYP3A4 inducer; and clozapine does produce QTc prolongation as a known side effect; the risperidone metabolite accumulation story described is pharmacokinetically fabricated.
6. A 55-year-old man presents to a neurology clinic after his sleep partner of 20 years insists he be evaluated. For the past 8 years he has had markedly reduced sense of smell, chronic constipation, and for the past 5 years has been acting out his dreams — shouting and striking out during sleep, confirmed on polysomnography as REM sleep behavior disorder (RBD). His neurological examination is entirely normal with no motor features of parkinsonism. A DAT-SPECT (DaTscan) is mildly reduced bilaterally. He asks the neurologist what this all means and whether he has Parkinson's disease. Which of the following best characterizes this clinical picture and the appropriate counseling?
A) This presentation is consistent with essential tremor with autonomic features; RBD and anosmia can occur in essential tremor due to cerebello-thalamic circuit involvement in autonomic regulation; the mildly reduced DaTscan reflects normal aging-related DAT decline; the patient should be reassured that he does not have a neurodegenerative disease and no monitoring is needed
B) This presentation is consistent with multiple system atrophy (MSA) in its pre-motor phase; anosmia, constipation, and RBD are cardinal features of MSA-P; the mildly reduced DaTscan confirms early MSA-related dopaminergic degeneration; he should be counseled that MSA is the most likely diagnosis and started on levodopa to slow early nigrostriatal degeneration
C) This presentation represents prodromal synucleinopathy — most likely pre-motor Parkinson's disease at Braak Stage 1–2, based on the combination of anosmia (olfactory bulb involvement), constipation (dorsal vagal nucleus and enteric nervous system involvement), and polysomnography-confirmed RBD (sublaterodorsal nucleus degeneration); the mildly reduced DaTscan suggests early nigrostriatal involvement has begun; he should be counseled that the majority of individuals with this prodromal profile eventually develop a defined synucleinopathy, currently no neuroprotective therapy is proven, and he should be monitored closely and considered for enrollment in clinical trials
D) This presentation confirms early Parkinson's disease and warrants immediate initiation of carbidopa/levodopa; the mildly reduced DaTscan combined with two or more prodromal non-motor features meets current diagnostic criteria for definite PD; delaying dopaminergic therapy in confirmed PD is associated with worse long-term motor outcomes and should be avoided
E) This presentation is most consistent with idiopathic RBD without systemic involvement; anosmia and constipation in a 55-year-old are coincidental findings unrelated to the RBD; the mildly reduced DaTscan is a false positive caused by normal inter-individual DAT variation; no further neurological evaluation is needed unless motor symptoms develop
ANSWER: C
Rationale:
This patient presents with the classic triad of prodromal synucleinopathy features: anosmia reflecting olfactory bulb Lewy body pathology (Braak Stage 1), constipation reflecting degeneration of the dorsal motor nucleus of the vagus and enteric nervous system (also Braak Stage 1–2), and polysomnography-confirmed REM sleep behavior disorder (RBD) reflecting degeneration of the sublaterodorsal nucleus and related pontine circuits responsible for REM sleep atonia. Together, these represent three of the most validated prodromal biomarkers of Parkinson's disease and related synucleinopathies. Longitudinal cohort studies have demonstrated that individuals with polysomnography-confirmed isolated RBD convert to a defined synucleinopathy — predominantly PD, dementia with Lewy bodies, or multiple system atrophy — at rates of approximately 6–7% per year, with conversion rates exceeding 80–90% over long-term follow-up. The mildly reduced DaTscan suggests that nigrostriatal dopaminergic terminal involvement has begun, though it has not yet crossed the symptomatic threshold. The absence of motor features means a clinical PD diagnosis cannot be made by current criteria (which require bradykinesia plus one additional cardinal feature), but the overall picture is highly consistent with prodromal PD at Braak Stage 1–2. Appropriate counseling includes honest disclosure of the high conversion risk, explanation that no proven neuroprotective therapy currently exists, establishment of close clinical monitoring, and referral for clinical trial enrollment — this prodromal population is a priority target for disease-modifying studies.
Option A: Option A is incorrect: essential tremor does not cause anosmia, RBD, or reduced DAT binding; DAT reduction is not a normal aging variant at this magnitude; this presentation is not consistent with essential tremor.
Option B: Option B is incorrect: while MSA can present with autonomic features and RBD, anosmia is not a cardinal feature of MSA and is much more characteristic of PD and DLB; MSA-P produces nigrostriatal degeneration but the classic MSA prodrome includes autonomic failure (orthostatic hypotension, bladder dysfunction) as more prominent features; and levodopa is not used to slow nigrostriatal degeneration.
Option D: Option D is incorrect: current Movement Disorder Society diagnostic criteria for PD require the presence of parkinsonism (bradykinesia plus at least one additional motor feature); prodromal biomarkers support risk stratification but do not substitute for motor features in establishing a definite PD diagnosis; initiating levodopa in the absence of symptoms is not standard practice.
Option E: Option E is incorrect: the combination of three validated prodromal biomarkers plus a mildly reduced DaTscan is not a coincidental finding; this cluster has high predictive value for synucleinopathy; normal inter-individual DAT variation does not produce consistently reduced bilateral binding; dismissing this presentation without close monitoring would be clinically inappropriate.
7. A 72-year-old man with a 7-year history of Parkinson's disease has been experiencing motor wearing-off. His neurologist increases his carbidopa/levodopa dose. Two weeks later his motor function is better, but he calls reporting daily near-fainting episodes when standing and one fall. His blood pressure drops from 142/88 mmHg supine to 94/60 mmHg standing. He was not experiencing these symptoms before the dose increase. Which of the following best explains the mechanism of his new orthostatic hypotension and identifies the most appropriate next step?
A) His orthostatic hypotension reflects the convergence of two mechanisms: autonomic degeneration from alpha-synuclein pathology in central and peripheral autonomic neurons (including the dorsal motor nucleus of the vagus and sympathetic ganglia) has already impaired his cardiovascular baroreflex; the levodopa dose increase worsened hypotension by increasing peripheral dopamine formation — peripheral dopamine acts as a vasodilator via vascular D1 receptors — beyond what his impaired autonomic reflexes can compensate for; the next step is to weigh the motor benefit against the cardiovascular risk, consider dose reduction or redistribution, and add a pharmacological pressor agent such as midodrine or droxidopa while pursuing non-pharmacological measures
B) His orthostatic hypotension is caused by levodopa-induced hyperprolactinemia from tuberoinfundibular pathway stimulation; elevated prolactin reduces adrenal cortisol synthesis and impairs the mineralocorticoid-mediated sodium retention needed to maintain plasma volume; management is to add fludrocortisone to replace the mineralocorticoid effect blunted by hyperprolactinemia
C) His orthostatic hypotension reflects levodopa-induced central sympatholysis; high-dose levodopa crosses the blood-brain barrier and produces excess dopamine in hypothalamic autonomic control centers, which suppresses sympathetic outflow through D2 receptor activation in the intermediolateral cell column of the spinal cord; management is to switch to a peripherally restricted formulation of levodopa that does not cross the blood-brain barrier
D) His orthostatic hypotension is a carbidopa side effect rather than a levodopa effect; carbidopa at high doses inhibits peripheral AADC to the point of blocking norepinephrine synthesis in sympathetic neurons, impairing vasoconstriction; management is to reduce carbidopa by switching to a lower carbidopa-to-levodopa ratio formulation
E) His orthostatic hypotension is caused by levodopa-induced depletion of pyridoxal phosphate (vitamin B6), which is a cofactor required for peripheral AADC; depleted pyridoxal phosphate impairs norepinephrine synthesis in sympathetic neurons and impairs the vasopressor response to orthostatic stress; management is to supplement vitamin B6 while continuing the current levodopa dose
ANSWER: A
Rationale:
Orthostatic hypotension in Parkinson's disease has two converging pathogenic mechanisms that this patient's clinical course illustrates directly. The first is disease-intrinsic: alpha-synuclein pathology spreads beyond the nigrostriatal system to affect autonomic neurons, including the dorsal motor nucleus of the vagus in the brainstem (involved in early Braak stages), sympathetic ganglionic neurons, and cardiac sympathetic terminals. This autonomic neurodegeneration progressively impairs the cardiovascular baroreflex — the reflex that normally compensates for the blood pressure drop on standing by increasing heart rate and peripheral vascular resistance. The second is iatrogenic: levodopa that escapes the blood-brain barrier is converted to dopamine by peripheral AADC in the systemic circulation despite carbidopa co-administration (some peripheral conversion always remains, particularly at higher doses). Peripheral dopamine acts as a vasodilator through vascular D1 receptor activation, reducing peripheral vascular resistance. In this patient, the pre-existing impaired baroreflex could compensate at his previous dose, but the dose increase tipped the balance — more peripheral dopamine-mediated vasodilation exceeded his baroreflex reserve, producing symptomatic orthostatic hypotension. Management requires balancing motor benefit against cardiovascular safety: options include modest dose reduction, redistributing doses to reduce peak peripheral dopamine, and adding pharmacological pressor agents — midodrine (alpha-1 agonist) or droxidopa (norepinephrine prodrug) — alongside non-pharmacological strategies such as increased salt and fluid intake, compression garments, and head-of-bed elevation.
Option B: Option B is incorrect: levodopa does not cause hyperprolactinemia — dopaminergic agents reduce prolactin by stimulating D2 receptors on pituitary lactotrophs; and hyperprolactinemia does not cause orthostatic hypotension through mineralocorticoid suppression in this clinical context.
Option C: Option C is incorrect: levodopa-induced central sympatholysis via hypothalamic D2 receptor activation is not an established mechanism of orthostatic hypotension in PD; the primary iatrogenic mechanism is peripheral dopamine-mediated vasodilation; and a peripherally restricted levodopa formulation that cannot cross the blood-brain barrier would have no therapeutic effect on PD motor symptoms.
Option D: Option D is incorrect: carbidopa inhibits peripheral AADC — the enzyme responsible for converting levodopa to dopamine — and does not inhibit the enzymatic pathway for norepinephrine synthesis in sympathetic neurons; AADC (tyrosine hydroxylase and DOPA decarboxylase) activity in sympathetic neurons is not meaningfully inhibited by carbidopa at therapeutic doses because sympathetic ganglia are outside the systemic circulation where carbidopa concentrations are active.
Option E: Option E is incorrect: while levodopa's decarboxylation does consume pyridoxal phosphate, clinical B6 deficiency causing impaired norepinephrine synthesis is not an established mechanism of levodopa-associated orthostatic hypotension; this hypothesis was a historical concern but is not the pharmacological explanation for the clinical phenomenon described.
8. A 68-year-old woman with Parkinson's disease on carbidopa/levodopa 25/100 mg four times daily reports that each dose wears off after about 3 hours, producing a predictable return of tremor and bradykinesia before her next scheduled dose. Rather than increasing the levodopa dose further — which she tolerates poorly due to nausea — her neurologist adds rasagiline 1 mg once daily. The patient asks how this tablet, taken once a day, can extend the benefit of a drug she takes four times daily. Which of the following best explains the mechanism by which rasagiline extends levodopa benefit in this setting?
A) Rasagiline inhibits hepatic COMT, reducing peripheral methylation of levodopa to 3-O-methyldopa; by preserving more circulating levodopa for CNS transport via LAT1, each carbidopa/levodopa dose produces higher peak brain levodopa concentrations and longer duration of therapeutic effect
B) Rasagiline increases the expression of dopamine D2 receptors on indirect pathway MSNs through a transcriptional mechanism; upregulated D2 receptors are more sensitive to the available dopamine, extending the duration of indirect pathway suppression from each levodopa dose and reducing wearing-off
C) Rasagiline irreversibly inhibits the dopamine transporter (DAT), preventing reuptake of released dopamine from the synapse; synaptic dopamine persists longer after each levodopa-derived dopamine release event, extending postsynaptic receptor occupancy and prolonging motor benefit beyond what the levodopa dose alone produces
D) Rasagiline competitively inhibits AADC in the CNS, slowing the conversion of levodopa to dopamine in the brain; by reducing the rate of dopamine formation, rasagiline extends the period over which dopamine accumulates centrally from each levodopa dose, smoothing the concentration-effect curve and reducing wearing-off
E) Rasagiline irreversibly inhibits MAO-B on the outer mitochondrial membrane of striatal neurons and glial cells, preventing the oxidative deamination of dopamine to DOPAC; by reducing the rate of dopamine catabolism in the striatum, rasagiline extends the half-life of dopamine derived from each levodopa dose, increasing both the duration and the nadir concentration of dopamine between doses and thereby reducing wearing-off without requiring a higher levodopa dose
ANSWER: E
Rationale:
Monoamine oxidase B (MAO-B) is located on the outer mitochondrial membrane of striatal neurons and astrocytes and is responsible for the oxidative deamination of a significant fraction of dopamine to DOPAC (3,4-dihydroxyphenylacetic acid) and hydrogen peroxide. Rasagiline is an irreversible, selective MAO-B inhibitor that forms a covalent adduct with the flavin adenine dinucleotide cofactor of MAO-B, permanently inactivating the enzyme; functional recovery requires synthesis of new MAO-B protein over weeks. Once MAO-B is irreversibly inhibited by a single daily rasagiline dose, the enzyme remains inhibited around the clock — explaining how a once-daily tablet continuously protects dopamine from catabolism regardless of when levodopa doses are taken. In the setting of levodopa-related wearing-off, rasagiline extends the duration and raises the trough concentration of striatal dopamine derived from each levodopa dose by reducing the rate at which it is cleared by MAO-B. This extends the interval of effective dopaminergic stimulation between doses, smoothing the motor response and reducing the symptomatic wearing-off without requiring a higher levodopa dose. The irreversible inhibition mechanism accounts for the pharmacodynamic duration far exceeding the plasma half-life of rasagiline itself.
Option A: Option A is incorrect: rasagiline is a selective MAO-B inhibitor and does not inhibit COMT; COMT inhibition is the mechanism of entacapone and tolcapone; if COMT inhibition were the mechanism, it would increase plasma levodopa availability but that is a different drug class and not the rasagiline mechanism.
Option B: Option B is incorrect: rasagiline does not upregulate D2 receptor expression through transcriptional mechanisms; receptor expression changes may occur with chronic dopaminergic manipulation but this is not the established mechanism of rasagiline's adjunctive benefit; MAO-B inhibition reducing dopamine catabolism is the direct mechanism.
Option C: Option C is incorrect: rasagiline does not inhibit the dopamine transporter (DAT); DAT inhibition is the mechanism of cocaine, methylphenidate, and related compounds; selegiline and rasagiline act specifically on MAO-B and have no clinically significant DAT-blocking activity at therapeutic doses.
Option D: Option D is incorrect: rasagiline does not inhibit AADC; it acts on MAO-B, which degrades dopamine after it has already been synthesized; inhibiting AADC would reduce the conversion of levodopa to dopamine and would be counterproductive, reducing rather than extending the therapeutic dopamine signal.
9. An 81-year-old man with a 13-year history of Parkinson's disease has developed progressive memory loss, visuospatial impairment, and executive dysfunction over the past two years, meeting criteria for Parkinson's disease dementia (PDD). His neurologist prescribes rivastigmine transdermal patch 4.6 mg/24 hours with plans to titrate to 9.5 mg/24 hours. His daughter, a nurse, asks why the physician chose rivastigmine rather than donepezil, which she knows from her work in Alzheimer's disease care. Which of the following best explains the rationale for rivastigmine over donepezil in this patient?
A) Rivastigmine is preferred because it crosses the blood-brain barrier more efficiently than donepezil via LAT1-mediated transport; its higher CNS bioavailability produces greater cholinesterase inhibition in the basal nucleus of Meynert projections; donepezil relies on passive diffusion and achieves lower brain concentrations in patients with Parkinson's disease whose blood-brain barrier permeability is reduced
B) Rivastigmine is the only cholinesterase inhibitor with FDA approval specifically for Parkinson's disease dementia, based on the EXPRESS trial which demonstrated significant improvement in cognition and global function compared to placebo in PDD patients; donepezil has regulatory approval for Alzheimer's disease dementia but not specifically for PDD; additionally, rivastigmine inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), whereas donepezil inhibits only AChE, providing broader cholinesterase inhibition relevant to the mixed AChE and BuChE activity in PDD cortex
C) Rivastigmine is preferred because donepezil is contraindicated in Parkinson's disease patients on levodopa; donepezil inhibits CYP2D6 and blocks the hepatic metabolism of levodopa, causing toxic levodopa accumulation and severe dyskinesias; rivastigmine does not interact with levodopa metabolism
D) Rivastigmine is preferred because it is a reversible competitive inhibitor of AChE that is rapidly metabolized, allowing dose titration without risk of cholinergic excess; donepezil is an irreversible AChE inhibitor with a 70-hour half-life that cannot be titrated safely in elderly PD patients who are sensitive to cholinergic side effects
E) Rivastigmine is preferred because it has a secondary mechanism of action as a weak D3 receptor partial agonist, providing mild dopaminergic support in the limbic and cortical circuits affected by PDD in addition to cholinesterase inhibition; donepezil has no dopaminergic activity and therefore addresses only the cholinergic component of the PDD pathology
ANSWER: B
Rationale:
Rivastigmine is the only pharmacological agent with regulatory approval specifically for Parkinson's disease dementia (PDD). Its approval was based on the EXPRESS trial (Exelon in Parkinson's Disease Dementia Study), a randomized, double-blind, placebo-controlled trial that demonstrated statistically significant improvement in the primary cognitive endpoint (ADAS-cog scale) and clinician's global impression of change in patients with mild-to-moderate PDD. Donepezil — despite extensive evidence in Alzheimer's disease dementia — does not have a specific regulatory approval for PDD; while it has been studied in PDD with some positive findings, the regulatory designation matters for evidence-based prescribing and formulary decisions. Beyond the regulatory distinction, rivastigmine inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) — a dual inhibition profile that may be advantageous in PDD, where BuChE activity is upregulated in the cortex as AChE-expressing neurons degenerate and BuChE-expressing glial cells become more prominent in the cholinesterase pool. Donepezil selectively inhibits AChE and does not meaningfully inhibit BuChE. The transdermal patch formulation of rivastigmine achieves lower peak plasma concentrations than the oral capsule, reducing the nausea and vomiting that are the primary dose-limiting side effects of cholinesterase inhibitors.
Option A: Option A is incorrect: rivastigmine crosses the blood-brain barrier by passive diffusion due to its lipophilicity, not via LAT1; LAT1 specifically transports large neutral amino acids and levodopa; BBB permeability is not meaningfully reduced in PD in a way that selectively impairs donepezil penetration.
Option C: Option C is incorrect: donepezil is not contraindicated with levodopa; donepezil does modestly inhibit CYP2D6, but levodopa is not metabolized by CYP2D6 — it is decarboxylated by AADC and methylated by COMT; there is no clinically significant pharmacokinetic interaction between donepezil and levodopa.
Option D: Option D is incorrect: both rivastigmine and donepezil are reversible cholinesterase inhibitors; donepezil is not irreversible — it binds reversibly to AChE with a long half-life (approximately 70 hours) but the enzyme is not permanently inactivated; rivastigmine is sometimes described as pseudo-irreversible because its carbamylation of AChE is slowly reversible over hours, but neither drug is a true irreversible inhibitor; and the dose titration rationale described does not correctly characterize the pharmacological distinction between them.
Option E: Option E is incorrect: rivastigmine has no established D3 receptor partial agonist activity; it is a pure cholinesterase inhibitor without dopaminergic receptor pharmacology; attributing a secondary dopaminergic mechanism to rivastigmine is pharmacologically incorrect.
10. A 64-year-old man with Parkinson's disease and medically refractory motor fluctuations is being evaluated for deep brain stimulation (DBS). The neurosurgeon explains that there are two standard DBS targets — the subthalamic nucleus (STN) and the globus pallidus interna (GPi) — and asks the resident to explain the circuit mechanism by which each produces motor benefit and how they differ in clinical implications. Which of the following correctly contrasts the circuit mechanisms of STN DBS and GPi DBS and identifies a clinically important difference between the two targets?
A) STN DBS produces motor benefit by activating the hyperdirect cortico-STN pathway, which overrides the abnormal basal ganglia output signal with a rhythmic cortical reset; GPi DBS produces motor benefit by activating antidromic projections from the GPi to the striatum, restoring dopaminergic tone in the direct pathway; STN DBS is preferred because it is more effective for tremor while GPi DBS is preferred for bradykinesia
B) STN DBS produces motor benefit by inducing a lesion effect — high-frequency stimulation causes local excitotoxic damage to STN neurons, permanently reducing STN output; GPi DBS works by the same excitotoxic mechanism at the GPi; STN DBS is preferred because STN excitotoxic lesions are smaller and carry lower risk of permanent dysarthria than GPi lesions
C) STN DBS and GPi DBS produce motor benefit through identical circuit mechanisms — both drive antidromic action potentials into the thalamus that depolarize thalamic relay neurons and increase thalamocortical excitatory drive; the only clinical difference is that GPi DBS requires higher current settings and therefore has greater battery drain, making STN DBS the standard first choice for battery conservation
D) STN DBS reduces the hyperactivity of the subthalamic nucleus — which in PD is disinhibited by reduced GPe activity and drives excessive glutamatergic excitation of the GPi and SNr — thereby reducing GPi/SNr inhibitory output to the thalamus and restoring thalamocortical drive; GPi DBS directly reduces the inhibitory output of the GPi to the thalamus, bypassing the upstream STN mechanism and achieving the same downstream thalamic disinhibition; a clinically important difference is that STN DBS allows greater reduction in dopaminergic medication requirements post-operatively, while GPi DBS better tolerates ongoing levodopa without causing stimulation-induced dyskinesias, making GPi DBS preferable in patients with prominent levodopa-induced dyskinesias
E) STN DBS produces motor benefit by blocking glutamate release from STN terminals through presynaptic calcium channel inhibition, reducing excitatory drive to both GPi and cerebellum; GPi DBS produces motor benefit by blocking GABA release from GPi terminals through the same presynaptic mechanism, reducing thalamic inhibition; the clinical difference is that STN DBS also reduces cerebellar tremor while GPi DBS does not, making STN DBS the standard choice for tremor-predominant PD
ANSWER: D
Rationale:
In Parkinson's disease, the subthalamic nucleus is hyperactive because loss of nigrostriatal dopamine removes D2-mediated inhibition of indirect pathway MSNs, increasing their GABAergic suppression of the GPe, disinhibiting the STN and allowing it to fire excessively. The hyperactive STN drives glutamatergic excitation of the GPi and SNr, which increases their GABAergic inhibitory output to the thalamus and reduces thalamocortical motor drive, producing bradykinesia and hypokinesia. STN DBS at high frequencies modulates this circuit by reducing the net hyperactive output of the STN — through mechanisms including efferent axon stimulation effects and local circuit modulation — decreasing its glutamatergic drive to the GPi/SNr, reducing their output, and restoring thalamocortical drive. GPi DBS targets the output nucleus directly: high-frequency stimulation of the GPi reduces its inhibitory output to the thalamus, achieving the same downstream thalamic disinhibition without needing to modulate the upstream STN. Both targets are clinically effective for the cardinal motor features of PD. The most important practical distinction is that STN DBS typically allows substantial reduction (often 50% or more) in post-operative dopaminergic medication requirements — a significant benefit in terms of side effect burden — while GPi DBS does not reduce medication requirements as effectively; however, GPi DBS is better tolerated when levodopa-induced dyskinesias are prominent pre-operatively, because GPi stimulation directly suppresses dyskinesias whereas STN stimulation can exacerbate them if medications are not simultaneously reduced.
Option A: Option A is incorrect: while a hyperdirect cortico-STN pathway does exist and is engaged by STN DBS, this is not the established primary therapeutic circuit mechanism; antidromic GPi-to-striatum restoration of dopaminergic tone is not an established DBS mechanism; and the tremor vs. bradykinesia target dichotomy described is not the standard clinical distinction between STN and GPi DBS.
Option B: Option B is incorrect: DBS does not produce therapeutic benefit through excitotoxic neuronal damage; the stimulation parameters are designed to modulate circuit activity without producing lesions; high-frequency DBS is reversible and adjustable, which distinguishes it from ablative procedures.
Option C: Option C is incorrect: STN DBS and GPi DBS do not produce motor benefit through antidromic thalamic depolarization; the motor benefit flows from reduced GPi/SNr inhibitory output to the thalamus, not from antidromic thalamic activation; and the difference between the two targets is not merely battery consumption.
Option E: Option E is incorrect: the presynaptic calcium channel blockade mechanism of glutamate and GABA release inhibition is not the established mechanism of DBS at either target; and STN DBS does not specifically reduce cerebellar tremor through cerebellar glutamate suppression; the tremor circuit distinction is more nuanced than this option suggests.
11. A 52-year-old woman has just been diagnosed with Parkinson's disease. Genetic testing reveals a heterozygous GBA N370S variant. She has no family history of Gaucher disease and has no systemic signs of glucocerebrosidase deficiency. She asks her neurologist what this result means for her prognosis and whether it changes her treatment. Which of the following best characterizes the prognostic implications of a GBA variant in this patient and the current state of GBA-targeted therapy?
A) A heterozygous GBA variant in a newly diagnosed PD patient has no prognostic significance; GBA-associated PD has identical motor progression rates, cognitive outcomes, and treatment responses to idiopathic PD; the variant is relevant only for carrier testing of her children to assess their Gaucher disease risk, not for her own PD management
B) A heterozygous GBA variant confirms that her PD is caused by Gaucher disease type 3 (neuronopathic Gaucher disease); she should be urgently referred to a metabolic specialist for enzyme replacement therapy with imiglucerase, which will treat the underlying lysosomal storage disorder and slow the nigrostriatal degeneration; standard PD medications are contraindicated with enzyme replacement therapy
C) A heterozygous GBA variant is the most common known genetic risk factor for sporadic PD and carries important prognostic information: GBA-associated PD is characterized by earlier age of onset (consistent with her presentation at age 52), a higher rate of cognitive decline, and a greater lifetime risk of Parkinson's disease dementia compared to idiopathic PD; penetrance is incomplete — many GBA carriers never develop PD; standard dopaminergic therapy is used for motor symptoms; GBA-targeted investigational therapies including pharmacological chaperones and gene therapy approaches are in clinical development and she may be eligible for trials
D) A heterozygous GBA variant indicates that her PD will follow an exclusively tremor-predominant phenotype throughout its course; GBA-associated PD does not progress to dementia because the lysosomal dysfunction causes alpha-synuclein to accumulate preferentially in the SNpc rather than cortical neurons; standard PD motor therapy is appropriate and no enhanced cognitive monitoring is needed
E) A heterozygous GBA variant means her PD is fully autosomal dominant with 50% penetrance; each of her children has a 50% chance of inheriting the variant and a 50% chance of developing PD if they inherit it; she should be counseled that all her children should undergo prophylactic levodopa therapy starting at age 40 to delay nigrostriatal degeneration before symptoms develop
ANSWER: C
Rationale:
Heterozygous GBA variants — including N370S, the most common GBA variant in populations of European and Ashkenazi Jewish ancestry — are the most common known genetic risk factor for sporadic Parkinson's disease, found in approximately 5–15% of PD patients depending on the population. The presence of a GBA variant in a newly diagnosed PD patient carries specific and clinically actionable prognostic information. First, GBA-associated PD is characterized by earlier age of onset compared to idiopathic PD — consistent with this patient's presentation at 52, which is younger than typical idiopathic PD onset. Second, GBA-associated PD has a significantly higher rate of cognitive decline and a greater lifetime risk of Parkinson's disease dementia (PDD) than idiopathic PD, likely reflecting the lysosomal dysfunction-alpha-synuclein feedforward loop that promotes more widespread cortical Lewy body pathology. Third, penetrance is incomplete — the majority of heterozygous GBA carriers in the general population will not develop PD, meaning the variant confers risk rather than certainty of disease. For motor symptoms, standard dopaminergic therapy (carbidopa/levodopa, dopamine agonists) is used, as GBA-associated PD responds to these agents similarly to idiopathic PD. The GBA variant does change the surveillance plan — more proactive cognitive monitoring is warranted — and opens eligibility for GBA-targeted clinical trials. Investigational approaches under study include pharmacological chaperones such as ambroxol that may enhance residual glucocerebrosidase activity and improve lysosomal alpha-synuclein clearance, and gene therapy approaches targeting GBA expression restoration.
Option A: Option A is incorrect: a GBA variant does have significant prognostic implications for the patient's own PD course — earlier onset, faster cognitive decline, higher dementia risk — and these are clinically important for monitoring, counseling, and trial eligibility; dismissing prognostic significance is incorrect.
Option B: Option B is incorrect: heterozygous GBA variants do not cause Gaucher disease; Gaucher disease requires homozygous or compound heterozygous biallelic GBA loss; type 3 (neuronopathic) Gaucher disease is a biallelic condition; enzyme replacement therapy with imiglucerase does not cross the blood-brain barrier and is not used for GBA-associated PD; standard PD medications are not contraindicated with enzyme replacement.
Option D: Option D is incorrect: GBA-associated PD does not follow an exclusively tremor-predominant phenotype and does progress to dementia — the higher dementia risk compared to idiopathic PD is one of the most consistent findings in GBA-PD natural history studies; the claim that lysosomal dysfunction restricts alpha-synuclein accumulation to the SNpc contradicts the established pathological evidence showing widespread cortical Lewy body pathology in GBA-PD.
Option E: Option E is incorrect: GBA heterozygous variants do not follow autosomal dominant inheritance with 50% penetrance; penetrance is substantially lower than 50% — most heterozygous carriers in the general population do not develop PD; prophylactic levodopa in asymptomatic GBA carriers is not established practice and could cause harm without demonstrated benefit.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.